{"hands_on_practices": [{"introduction": "A robust pharmacoeconomic analysis begins with a comprehensive accounting of all relevant costs and outcomes. This exercise provides foundational practice in classifying costs from a societal perspective—distinguishing between direct medical, direct non-medical, and indirect costs—and in quantifying health effects as Quality-Adjusted Life-Years (QALYs). Mastering this initial step is critical for building a valid model that accurately reflects the full impact of a healthcare intervention [@problem_id:4584711].", "problem": "An oncology clinic is evaluating the short-horizon economic impact of a single chemotherapy cycle from a societal perspective. In pharmacoeconomic analysis, costs are commonly categorized as direct medical costs (resources directly associated with medical care delivery such as medications and clinician services), direct non-medical costs (non-healthcare goods and services consumed because of care seeking such as transportation and lodging), indirect costs (productivity losses due to morbidity or informal caregiver time), and intangible costs (non-monetary burdens such as pain or suffering that are reflected as decrements in health-related quality of life). For one cycle, the following items are observed: drug acquisition $\\$2{,}500$ per cycle, infusion chair time $2$ hours at $\\$80$ per hour, caregiver time $4$ hours at $\\$25$ per hour, travel $30$ miles at $\\$0.58$ per mile, productivity loss $1$ workday valued at $\\$200$, and nausea-related discomfort represented as a temporary utility decrement of $0.05$ for $3$ days.\n\nAdopt a societal perspective over the $3$-day post-infusion window. First, conceptualize these categories in your own words as above and classify each item accordingly. Then, compute the total cost across direct medical, direct non-medical, and indirect categories for this cycle. Treat the nausea discomfort as an intangible cost that manifests as a health effect: convert the utility decrement to a quality-adjusted life-year (QALY) loss using the definition of a quality-adjusted life-year (QALY) as the integral of utility over time. Using a willingness-to-pay (WTP) threshold of $\\$100{,}000$ per QALY, compute the Net Monetary Benefit (NMB) over this $3$-day window relative to a comparator with no costs and no utility decrement over the same window.\n\nExpress the final result as a single number equal to the NMB in dollars. Round your answer to four significant figures. Do not include the unit in your final boxed answer.", "solution": "The problem statement is evaluated to be valid. It is scientifically grounded in the principles of pharmacoeconomics, well-posed with sufficient information for a unique solution, and objective in its presentation. The problem requires a multi-step calculation based on standard methodologies in health technology assessment.\n\nThe analysis proceeds in four parts: 1. Classification of costs; 2. Calculation of total monetized costs; 3. Calculation of health effects in quality-adjusted life-years (QALYs); and 4. Calculation of the Net Monetary Benefit (NMB).\n\n**1. Conceptualization and Classification of Costs**\n\nFrom a societal perspective, costs encompass all resources consumed, regardless of who bears the financial burden. The categories are defined and applied as follows:\n\n-   **Direct Medical Costs:** These are costs for goods and services directly related to the provision of medical care. They represent the consumption of healthcare resources.\n    -   Drug acquisition: $\\$2,500$. This is a direct medical cost.\n    -   Infusion chair time: $2$ hours at $\\$80$ per hour. This is a cost for a medical service, hence a direct medical cost.\n\n-   **Direct Non-Medical Costs:** These are costs for non-healthcare goods and services that are necessary for the patient to receive care.\n    -   Travel: $30$ miles at $\\$0.58$ per mile. This cost is incurred to access care, making it a direct non-medical cost.\n\n-   **Indirect Costs:** These are costs associated with lost productivity due to morbidity, disability, or mortality. In a societal perspective, time spent by informal (unpaid) caregivers is also valued and included as a productivity loss.\n    -   Caregiver time: $4$ hours at $\\$25$ per hour. This represents the opportunity cost of the caregiver's time, an indirect cost.\n    -   Productivity loss: $1$ workday valued at $\\$200$. This is the patient's lost productivity, an indirect cost.\n\n-   **Intangible Costs:** These are non-monetary burdens of disease or treatment, such as pain, suffering, and anxiety. In pharmacoeconomics, these are not typically assigned a direct monetary value but are captured on the \"effects\" side of a cost-effectiveness analysis through quality-of-life or utility measures.\n    -   Nausea-related discomfort: A utility decrement of $0.05$ for $3$ days. This is an intangible cost, which will be quantified as a loss in QALYs.\n\n**2. Calculation of Total Societal Cost ($\\Delta C$)**\n\nThe total cost, which represents the incremental cost ($\\Delta C$) relative to the zero-cost comparator, is the sum of the direct medical, direct non-medical, and indirect costs.\n\nThe direct medical cost, $C_{DM}$, is the sum of the drug cost and the infusion service cost:\n$$C_{DM} = \\$2,500 + (2 \\text{ hours} \\times \\$80/\\text{hour}) = \\$2,500 + \\$160 = \\$2,660$$\n\nThe direct non-medical cost, $C_{DNM}$, is the travel cost:\n$$C_{DNM} = 30 \\text{ miles} \\times \\$0.58/\\text{mile} = \\$17.40$$\n\nThe indirect cost, $C_{I}$, is the sum of the caregiver's time value and the patient's productivity loss:\n$$C_{I} = (4 \\text{ hours} \\times \\$25/\\text{hour}) + \\$200 = \\$100 + \\$200 = \\$300$$\n\nThe total societal cost, $\\Delta C$, is the sum of these components:\n$$\\Delta C = C_{DM} + C_{DNM} + C_{I} = \\$2,660 + \\$17.40 + \\$300 = \\$2,977.40$$\n\n**3. Calculation of Incremental Health Effect ($\\Delta E$)**\n\nThe health effect is measured in QALYs. A QALY is the product of a health state's utility value and the time duration spent in that state, where time is measured in years. The problem describes a short-term side effect (nausea) causing a utility decrement of $\\Delta U = 0.05$ for a duration of $T = 3$ days. The comparator scenario involves no cost and no utility decrement, meaning the utility is maintained at the reference value of $1$.\n\nThe incremental QALY, $\\Delta E$, is the difference in QALYs between the chemotherapy intervention and the comparator over the $3$-day window. The QALY loss due to the side effect is the magnitude of the utility decrement multiplied by the duration in years. For precision, we use $365.25$ days per year.\n$$ \\Delta E = E_{\\text{chemo}} - E_{\\text{comparator}} = \\left( (1 - \\Delta U) \\times \\frac{T}{365.25} \\right) - \\left( 1 \\times \\frac{T}{365.25} \\right) $$\n$$ \\Delta E = -\\Delta U \\times \\frac{T}{365.25} $$\nSubstituting the given values:\n$$ \\Delta E = -0.05 \\times \\frac{3}{365.25} = -\\frac{0.15}{365.25} \\text{ QALYs} $$\n$$ \\Delta E \\approx -0.0004106775 \\text{ QALYs} $$\nThis negative value represents a net loss in quality-adjusted life over the specified period due to the treatment's side effects.\n\n**4. Calculation of Net Monetary Benefit (NMB)**\n\nThe NMB framework converts health effects ($\\Delta E$) into a monetary value using a willingness-to-pay (WTP) threshold, denoted by $\\lambda$, and subtracts the incremental costs ($\\Delta C$). The formula is:\n$$ NMB = (\\lambda \\times \\Delta E) - \\Delta C $$\nThe problem provides a WTP threshold of $\\lambda = \\$100,000$ per QALY. We use the previously calculated values for $\\Delta E$ and $\\Delta C$.\n$$ NMB = \\left( \\$100,000/\\text{QALY} \\times \\left( -\\frac{0.15}{365.25} \\text{ QALYs} \\right) \\right) - \\$2,977.40 $$\nFirst, we calculate the monetized value of the QALY loss:\n$$ \\lambda \\times \\Delta E = \\$100,000 \\times (-0.0004106775) \\approx -\\$41.06775 $$\nNow, we subtract the total cost:\n$$ NMB \\approx -\\$41.06775 - \\$2,977.40 = -\\$3,018.46775 $$\nThe problem asks for the result to be rounded to four significant figures. The value is $-\\$3,018.46775$. The first four significant figures are $3$, $0$, $1$, and $8$. The fifth digit is $4$, so we round down (i.e., truncate at the fourth significant digit).\n$$ NMB \\approx -\\$3,018 $$\nThe negative NMB indicates that, over this very short $3$-day horizon and considering only the specified costs and side effects, the chemotherapy cycle represents a net loss from a societal perspective compared to a baseline of no intervention.", "answer": "$$\\boxed{-3018}$$", "id": "4584711"}, {"introduction": "When comparing multiple treatment strategies, it is inefficient to evaluate every possible pair. This practice introduces the essential concepts of strict and extended (or weak) dominance, which serve as a formal method for identifying and eliminating strategies that are unambiguously poor value for money. By applying these rules, you will learn to construct the cost-effectiveness frontier, ensuring that subsequent incremental analysis focuses only on the set of potentially optimal interventions [@problem_id:4584773].", "problem": "A hospital is evaluating three mutually exclusive treatment strategies for a chronic condition over a fixed time horizon. The outcomes are measured as quality-adjusted life-years (QALYs), defined as quality-adjusted life-year (QALY), and the costs are fully loaded direct medical costs. The strategies have the following total discounted outcomes: QALYs of $1.00$, $1.10$, and $1.08$, and costs (in United States dollars) of $9{,}000$, $12{,}000$, and $15{,}000$, respectively. Assume that higher QALYs are better and higher costs are worse. Assume additivity of costs and QALYs across health states within each strategy and that the strategies are mutually exclusive.\n\nTasks:\n1) Using fundamental definitions in incremental cost-effectiveness analysis, define strict dominance and weak (extended) dominance in terms of cost $C$ and effectiveness $E$ measured in QALYs, without appealing to any shortcut formulas.\n2) Order the three strategies by effectiveness from least to most effective. Identify any strategies that are strictly dominated or weakly (extended) dominated based on this ordering and the pairwise incremental relationships.\n3) Remove any dominated strategies and perform incremental analysis on the remaining non-dominated set to determine the incremental cost per incremental QALY of the cost-effectiveness frontier.\n\nReport only the final incremental cost-effectiveness ratio of the frontier as a single number in dollars per QALY. Round your answer to $3$ significant figures. Express the final value in dollars per QALY.", "solution": "The problem is first validated by formal examination of its components.\n\nThe givens are:\nThree mutually exclusive treatment strategies are to be evaluated.\nStrategy 1: Cost $C_1 = \\$9,000$, Effectiveness $E_1 = 1.00$ QALYs.\nStrategy 2: Cost $C_2 = \\$12,000$, Effectiveness $E_2 = 1.10$ QALYs.\nStrategy 3: Cost $C_3 = \\$15,000$, Effectiveness $E_3 = 1.08$ QALYs.\nHigher effectiveness (QALYs) is preferred, and lower cost is preferred.\n\nThe problem is scientifically grounded in the established principles of cost-effectiveness analysis within pharmacoeconomics. It is well-posed, providing all necessary and consistent data for a unique solution. The language is objective and unambiguous. The values provided are plausible for medical interventions. Therefore, the problem is deemed valid and a solution can be derived.\n\nThe tasks will be addressed in sequence.\n\n1) Definition of Dominance in Incremental Cost-Effectiveness Analysis\n\nLet there be two treatment strategies, Strategy $A$ and Strategy $B$, with associated costs $C_A$ and $C_B$, and effectiveness measures $E_A$ and $E_B$, respectively.\n\nStrict Dominance: A strategy is strictly dominated if there is another strategy that is both more effective and less costly. Specifically, Strategy $B$ is strictly dominated by Strategy $A$ if and only if $C_A  C_B$ and $E_A  E_B$. A strictly dominated strategy is unequivocally inferior and should be removed from consideration.\n\nWeak (Extended) Dominance: This concept arises in the comparison of three or more strategies. When strategies are ordered by increasing effectiveness, an intermediate strategy is considered weakly or extendedly dominated if the incremental cost-effectiveness ratio (ICER) to reach it from a less effective strategy is greater than the ICER to reach a more effective strategy from that same baseline. Let strategies $A$, $B$, and $C$ be ordered by increasing effectiveness, such that $E_A  E_B  E_C$. Strategy $B$ is weakly dominated if the ICER of moving from $A$ to $B$ is greater than the ICER of moving from $A$ to $C$. Mathematically, this is expressed as:\n$$ \\frac{C_B - C_A}{E_B - E_A}  \\frac{C_C - C_A}{E_C - E_A} $$\nThis implies that Strategy $B$ lies above the line segment connecting strategies $A$ and $C$ on the cost-effectiveness plane, making it an inefficient choice.\n\n2) Identification of Dominated Strategies\n\nFirst, the three strategies are ordered by increasing effectiveness (QALYs):\nStrategy 1: $(E_1, C_1) = (1.00, \\$9,000)$\nStrategy 3: $(E_3, C_3) = (1.08, \\$15,000)$\nStrategy 2: $(E_2, C_2) = (1.10, \\$12,000)$\n\nNext, we check for dominance based on this ordering. We compare each strategy to others to identify any that are less effective and more costly, or more effective and less costly.\n\nLet's compare Strategy 2 and Strategy 3.\nEffectiveness: $E_2 = 1.10$ QALYs and $E_3 = 1.08$ QALYs. So, $E_2  E_3$.\nCosts: $C_2 = \\$12,000$ and $C_3 = \\$15,000$. So, $C_2  C_3$.\nSince Strategy 2 is both more effective ($E_2  E_3$) and less costly ($C_2  C_3$) than Strategy 3, Strategy 3 is strictly dominated by Strategy 2. Therefore, Strategy 3 is removed from further analysis as it would never be a cost-effective choice.\n\nNo other pairs exhibit strict dominance. The remaining strategies are Strategy 1 and Strategy 2. With only two strategies, the concept of weak (extended) dominance does not apply, as it requires an intermediate option.\n\n3) Incremental Analysis of the Non-Dominated Set\n\nThe non-dominated set, which constitutes the cost-effectiveness frontier, consists of Strategy 1 and Strategy 2.\nStrategy 1: $(E_1, C_1) = (1.00, \\$9,000)$\nStrategy 2: $(E_2, C_2) = (1.10, \\$12,000)$\n\nTo determine the incremental cost per incremental QALY, we calculate the Incremental Cost-Effectiveness Ratio (ICER) for moving from the less effective/less costly strategy (Strategy 1) to the more effective/more costly strategy (Strategy 2).\n\nThe formula for the ICER is:\n$$ \\text{ICER} = \\frac{\\Delta C}{\\Delta E} = \\frac{C_2 - C_1}{E_2 - E_1} $$\n\nSubstituting the given values:\n$$ \\text{ICER} = \\frac{\\$12,000 - \\$9,000}{1.10 - 1.00} $$\n$$ \\text{ICER} = \\frac{\\$3,000}{0.10 \\text{ QALYs}} $$\n$$ \\text{ICER} = \\$30,000 \\text{ per QALY} $$\n\nThe problem requires the answer to be rounded to $3$ significant figures. The calculated value is exactly $30,000$. To express this unambiguously with $3$ significant figures, we can write it in scientific notation as $3.00 \\times 10^4$. This single ICER value represents the incremental cost per incremental QALY for the entire cost-effectiveness frontier beyond the baseline strategy.", "answer": "$$\\boxed{3.00 \\times 10^4}$$", "id": "4584773"}, {"introduction": "The results of any economic model are subject to uncertainty in its input parameters. This hands-on problem demonstrates the use of one-way sensitivity analysis, a core technique for exploring how the Incremental Cost-Effectiveness Ratio (ICER) and the resulting decision can change when a key parameter is varied across a plausible range. By determining the threshold value at which an intervention becomes cost-effective, you gain a deeper understanding of a model's robustness and its most influential drivers [@problem_id:4584774].", "problem": "A hospital formulary committee is evaluating a new antithrombotic agent versus standard therapy over a horizon of $1$ year for adults at risk of ischemic stroke. Assume perfect adherence and that, at most, one stroke event can occur per patient-year. Under standard therapy, the annual probability of stroke is $p_{s} = 0.30$, and under the new agent it is $p_{n} = 0.18$. A stroke event causes a temporary quality-of-life reduction quantified as a utility decrement $d$ on the $[0,1]$ utility scale, lasting exactly $T = 1$ year. Baseline utility without stroke is the same under both strategies, and all other health outcomes are identical.\n\nThe new agent has an incremental acquisition cost of $C_{A} = \\$4{,}000$ per patient-year relative to standard therapy. Each stroke event incurs a direct medical cost of $C_{E} = \\$15{,}000$. Ignore discounting and any mortality differences within the $1$-year horizon.\n\nUsing the foundational definitions of Quality-Adjusted Life Year (QALY) and Incremental Cost-Effectiveness Ratio (ICER), perform a one-way sensitivity analysis on the utility decrement $d$ ranging from $0.05$ to $0.20$ by deriving the analytic expression for $\\mathrm{ICER}(d)$ that reflects how $d$ affects the expected incremental QALYs and costs. Then, using a willingness-to-pay threshold $\\lambda = \\$100{,}000$ per Quality-Adjusted Life Year (QALY), determine the value $d^{\\star}$ at which the intervention is exactly cost-effective, that is, $\\mathrm{ICER}(d^{\\star}) = \\lambda$.\n\nExpress the final $d^{\\star}$ as a unitless proportion on the QALY scale. Round your final numerical answer to four significant figures.", "solution": "The problem is valid as it is scientifically grounded, well-posed, objective, and contains sufficient information for a unique solution within the standard framework of pharmacoeconomics.\n\nThe Incremental Cost-Effectiveness Ratio (ICER) is defined as the ratio of the incremental cost ($\\Delta C$) to the incremental effectiveness ($\\Delta E$). In this context, effectiveness is measured in Quality-Adjusted Life Years (QALYs). The formula for the ICER is:\n$$ \\mathrm{ICER} = \\frac{\\Delta C}{\\Delta E} = \\frac{\\mathrm{E}[\\text{Cost}_{\\text{new}}] - \\mathrm{E}[\\text{Cost}_{\\text{standard}}]}{\\mathrm{E}[\\text{QALY}_{\\text{new}}] - \\mathrm{E}[\\text{QALY}_{\\text{standard}}]} $$\nLet the subscript 'n' denote the new antithrombotic agent and 's' denote the standard therapy.\n\nFirst, we determine the expected incremental cost, $\\Delta C$. The total cost for each strategy is the sum of the drug acquisition cost and the expected cost associated with a stroke event.\nThe incremental acquisition cost for the new agent is given as $C_{A} = \\$4{,}000$. The direct medical cost of a stroke event is $C_{E} = \\$15{,}000$.\nThe expected cost for standard therapy, over the $1$-year horizon, is the probability of a stroke multiplied by its cost:\n$$ \\mathrm{E}[\\text{Cost}_{\\text{s}}] = p_s \\cdot C_{E} + (1-p_s) \\cdot 0 = p_s C_{E} $$\nThe expected cost for the new agent includes its acquisition cost and the expected cost of a stroke:\n$$ \\mathrm{E}[\\text{Cost}_{\\text{n}}] = C_{A} + p_n \\cdot C_{E} $$\nThe incremental cost, $\\Delta C$, is the difference between the expected costs of the two strategies:\n$$ \\Delta C = \\mathrm{E}[\\text{Cost}_{\\text{n}}] - \\mathrm{E}[\\text{Cost}_{\\text{s}}] = (C_{A} + p_n C_{E}) - p_s C_{E} = C_{A} - (p_s - p_n)C_{E} $$\n\nNext, we determine the expected incremental effectiveness, $\\Delta E$, measured in QALYs. A QALY is the product of a health utility value and the time spent in that health state. The time horizon is $T=1$ year. Let the baseline utility for a patient without a stroke be $U_0$. A stroke event causes a utility decrement of $d$ for the entire $1$-year duration, resulting in a utility of $U_0 - d$.\nThe expected QALYs for a patient on standard therapy are calculated by weighting the QALYs in each health state (stroke vs. no stroke) by their respective probabilities:\n$$ \\mathrm{E}[\\text{QALY}_{\\text{s}}] = p_s \\cdot ((U_0 - d) \\cdot T) + (1-p_s) \\cdot (U_0 \\cdot T) $$\nGiven $T=1$ year:\n$$ \\mathrm{E}[\\text{QALY}_{\\text{s}}] = p_s(U_0 - d) + (1-p_s)U_0 = p_s U_0 - p_s d + U_0 - p_s U_0 = U_0 - p_s d $$\nSimilarly, the expected QALYs for a patient on the new agent are:\n$$ \\mathrm{E}[\\text{QALY}_{\\text{n}}] = p_n(U_0 - d) + (1-p_n)U_0 = p_n U_0 - p_n d + U_0 - p_n U_0 = U_0 - p_n d $$\nThe incremental effectiveness, $\\Delta E$, is the difference in expected QALYs. The baseline utility $U_0$ cancels out.\n$$ \\Delta E = \\mathrm{E}[\\text{QALY}_{\\text{n}}] - \\mathrm{E}[\\text{QALY}_{\\text{s}}] = (U_0 - p_n d) - (U_0 - p_s d) = p_s d - p_n d = (p_s - p_n)d $$\n\nWe can now formulate the analytic expression for the ICER as a function of the utility decrement $d$:\n$$ \\mathrm{ICER}(d) = \\frac{\\Delta C}{\\Delta E} = \\frac{C_{A} - (p_s - p_n)C_{E}}{(p_s - p_n)d} $$\nThis expression shows how the cost-effectiveness ratio changes with the utility decrement associated with a stroke.\n\nTo find the value $d^{\\star}$ at which the new agent is exactly cost-effective, we set the ICER equal to the given willingness-to-pay threshold, $\\lambda = \\$100{,}000$ per QALY.\n$$ \\mathrm{ICER}(d^{\\star}) = \\lambda $$\n$$ \\frac{C_{A} - (p_s - p_n)C_{E}}{(p_s - p_n)d^{\\star}} = \\lambda $$\nWe solve this equation for $d^{\\star}$:\n$$ (p_s - p_n)d^{\\star}\\lambda = C_{A} - (p_s - p_n)C_{E} $$\n$$ d^{\\star} = \\frac{C_{A} - (p_s - p_n)C_{E}}{(p_s - p_n)\\lambda} $$\n\nWe now substitute the numerical values provided in the problem statement:\n$p_s = 0.30$\n$p_n = 0.18$\n$C_A = 4000$\n$C_E = 15000$\n$\\lambda = 100000$\n\nFirst, calculate the absolute risk reduction, $p_s - p_n$:\n$$ p_s - p_n = 0.30 - 0.18 = 0.12 $$\nNext, calculate the value of the numerator, which is the incremental cost $\\Delta C$:\n$$ \\Delta C = C_{A} - (p_s - p_n)C_{E} = 4000 - (0.12)(15000) = 4000 - 1800 = 2200 $$\nNow, calculate the value of the denominator:\n$$ (p_s - p_n)\\lambda = (0.12)(100000) = 12000 $$\nSubstitute these results into the expression for $d^{\\star}$:\n$$ d^{\\star} = \\frac{2200}{12000} = \\frac{22}{120} = \\frac{11}{60} $$\n\nFinally, we compute the numerical value for $d^{\\star}$ and round it to four significant figures as required:\n$$ d^{\\star} = \\frac{11}{60} \\approx 0.183333\\dots $$\nRounding to four significant figures gives the final result:\n$$ d^{\\star} \\approx 0.1833 $$\nThis value of $d^{\\star}$ represents the utility decrement for a stroke at which the new agent's cost-effectiveness precisely matches the societal willingness-to-pay threshold.", "answer": "$$\\boxed{0.1833}$$", "id": "4584774"}]}